Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

558 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients.
DE Cremoux P, Hamy AS, Lehmann-Che J, Scott V, Sigal B, Mathieu MC, Bertheau P, Guinebretière JM, Pierga JY, Giacchetti S, Brain E, Marty M, Asselain B, Spyratos F, Bièche I. DE Cremoux P, et al. Among authors: scott v. Anticancer Res. 2018 Mar;38(3):1485-1490. doi: 10.21873/anticanres.12375. Anticancer Res. 2018. PMID: 29491076 Clinical Trial.
Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients.
de Cremoux P, Valet F, Gentien D, Lehmann-Che J, Scott V, Tran-Perennou C, Barbaroux C, Servant N, Vacher S, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Asselain B, Marty M, Spyratos F. de Cremoux P, et al. Among authors: scott v. BMC Cancer. 2011 Jun 1;11:215. doi: 10.1186/1471-2407-11-215. BMC Cancer. 2011. PMID: 21631949 Free PMC article. Clinical Trial.
Breast Cancer Index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy.
Mathieu MC, Mazouni C, Kesty NC, Zhang Y, Scott V, Passeron J, Arnedos M, Schnabel CA, Delaloge S, Erlander MG, André F. Mathieu MC, et al. Among authors: scott v. Ann Oncol. 2012 Aug;23(8):2046-2052. doi: 10.1093/annonc/mdr550. Epub 2011 Nov 22. Ann Oncol. 2012. PMID: 22112967 Free article.
Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer.
Arnedos M, Scott V, Job B, De La Cruz J, Commo F, Mathieu MC, Wolp-Diniz R, Richon C, Campone M, Bachelot T, Dalenc F, Dessen P, Lacroix L, Lazar V, Soria JC, Delaloge S, Andre F. Arnedos M, et al. Among authors: scott v. Eur J Cancer. 2012 Oct;48(15):2293-9. doi: 10.1016/j.ejca.2012.06.014. Epub 2012 Jul 26. Eur J Cancer. 2012. PMID: 22840369
Challenging single- and multi-probesets gene expression signatures of pathological complete response to neoadjuvant chemotherapy in breast cancer: experience of the REMAGUS 02 phase II trial.
Valet F, de Cremoux P, Spyratos F, Servant N, Dujaric ME, Gentien D, Lehmann-Che J, Scott V, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Pierga JY, Delaloge S, Giacchetti S, Brain E, Tembo O, Marty M, Asselain B. Valet F, et al. Among authors: scott v. Breast. 2013 Dec;22(6):1052-9. doi: 10.1016/j.breast.2013.08.015. Epub 2013 Oct 2. Breast. 2013. PMID: 24095610 Free article. Clinical Trial.
Whole exome sequencing of rare aggressive breast cancer histologies.
Dieci MV, Smutná V, Scott V, Yin G, Xu R, Vielh P, Mathieu MC, Vicier C, Laporte M, Drusch F, Guarneri V, Conte P, Delaloge S, Lacroix L, Fromigué O, André F, Lefebvre C. Dieci MV, et al. Among authors: scott v. Breast Cancer Res Treat. 2016 Feb;156(1):21-32. doi: 10.1007/s10549-016-3718-y. Epub 2016 Feb 23. Breast Cancer Res Treat. 2016. PMID: 26907767
BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.
Hamy AS, Bieche I, Lehmann-Che J, Scott V, Bertheau P, Guinebretière JM, Matthieu MC, Sigal-Zafrani B, Tembo O, Marty M, Asselain B, Spyratos F, de Cremoux P. Hamy AS, et al. Among authors: scott v. Breast Cancer Res Treat. 2016 Oct;159(3):499-511. doi: 10.1007/s10549-016-3961-2. Epub 2016 Sep 3. Breast Cancer Res Treat. 2016. PMID: 27592112
Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial.
Arnedos M, Bayar MA, Cheaib B, Scott V, Bouakka I, Valent A, Adam J, Leroux-Kozal V, Marty V, Rapinat A, Mazouni C, Sarfati B, Bieche I, Balleyguier C, Gentien D, Delaloge S, Lacroix-Triki M, Michiels S, Andre F. Arnedos M, et al. Among authors: scott v. Ann Oncol. 2018 Aug 1;29(8):1755-1762. doi: 10.1093/annonc/mdy202. Ann Oncol. 2018. PMID: 29893769 Free article. Clinical Trial.
558 results